Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · IEX Real-Time Price · USD
0.0729
+0.0039 (5.65%)
At close: Mar 27, 2024, 4:00 PM
0.0765
+0.0036 (4.94%)
Pre-market: Mar 28, 2024, 6:09 AM EDT
Jaguar Health Revenue
Jaguar Health had revenue of $10.72M in the twelve months ending September 30, 2023, down -0.51% year-over-year. Revenue in the quarter ending September 30, 2023 was $2.81M, a -10.70% decrease year-over-year. In the year 2022, Jaguar Health had annual revenue of $11.96M with 175.80% growth.
Revenue (ttm)
$10.72M
Revenue Growth
-0.51%
P/S Ratio
1.36
Revenue / Employee
$178,683
Employees
60
Market Cap
14.60M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
Dec 31, 2015 | 258.38K | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Acorda Therapeutics | 111.12M |
Star Equity Holdings | 45.79M |
T2 Biosystems | 11.00M |
Biomerica | 5.50M |
Immuron | 2.43M |
Talphera | 651.00K |
JAGX News
- 21 hours ago - Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates - Accesswire
- 7 days ago - GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market - Accesswire
- 4 weeks ago - Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance - Accesswire
- 5 weeks ago - Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 6 weeks ago - Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief - Accesswire
- 6 weeks ago - Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea - Accesswire
- 2 months ago - Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference - Accesswire
- 2 months ago - Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) - Accesswire